Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

A focused update to AAD’s adult AD guidelines recommends tapinarof, roflumilast, lebrikizumab, and nemolizumab based on high-certainty data, offering new options for those with mild to severe disease.

Physician Associates challenge outdated licensing rules to accelerate care, expand access, and ease the healthcare provider ...

Hydroxychloroquine is tied to reduced preeclampsia risk but not preterm birth risk in pregnant patients with lupus in a ...

While ADHD medications continue to reduce the risk for self-harm, injury, and car crashes, recent expanded prescribing ...

Delayed intracranial hemorrhage is uncommon in patients with mild traumatic brain injury receiving anticoagulant therapy, a study finds.

The American Heart Association’s PREVENT equations predict risk in subgroups of Asian and Hispanic people, a new study shows.

The prevalence of valley fever in 2019 was considerably higher than that reported through national surveillance.

A study published in Epidemiology in late May demonstrated that fine particulate matter in wildfire smoke represents a danger to human health considerably longer than a couple of days as previously ...

Waqar Qureshi, MD, of Baylor College of Medicine, reviews how the approach to diagnosis, management, and patient follow-up has changed since this disease entity was first described in 1955.

Expert Rev Endocrinol Metab. 2008;3(3):349-359. While the findings mentioned are reflective of patient populations in the respective studies, it is worth pointing out again that there is ...

Meloxicam is an enolcarboxamide with preferential COX-2 activity. Studies conducted on experimental models and human tissues indicate that meloxicam is a more potent inhibitor of COX-2 than COX-1 ...